Pan-KRAS inhibitors, such as the one described here, merit clinical testing in patients as they stand to affect the clinical outcomes of patients with KRAS-driven cancers, including those with lung, colorectal and pancreatic cancer as well as further less-frequent cancer types. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.